Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Hyperglycemia 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Lymphoma 2Leukemia 2Leukemia, Myeloid, Acute 1Insulin Resistance 1Hyperphagia 1Diabetes Mellitus, Type 2 1Congenital Abnormalities 1Burkitt Lymphoma 1

Interventions

Cyclophosphamide 160Rituximab 82Peripheral Blood Stem Cell Transplantation 78fludarabine phosphate 75Etoposide 69Filgrastim 67Methotrexate 59Cytarabine 58Vincristine 50Mycophenolic Acid 50Whole-Body Irradiation 48Radiotherapy 43Cyclosporine 43Busulfan 42Tacrolimus 40Melphalan 39Dexamethasone 37Prednisone 36Doxorubicin 36Antilymphocyte Serum 36fludarabine 31blinatumomab 27Methylprednisolone 24Granulocyte Colony-Stimulating Factor 22Carmustine 22Cord Blood Stem Cell Transplantation 21Calcium Dobesilate 18CT-P10 18Inotuzumab Ozogamicin 16sargramostim 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Burkitt Lymphoma × Insulin Glargine × Clear all
NCT00500240 2015-06-03

Effect of Tight Control of Blood Glucose During Hyper-CVAD Chemotherapy For Acute Lymphocytic Leukemia (ALL)

M.D. Anderson Cancer Center

Phase 3 Terminated
52 enrolled 8 charts
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Hyperglycemia, Leukemia, Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡